Arsenic inhibits myogenic differentiation and muscle regeneration

Environmental Health Perspectives

Volumn 118, Issue 7, 2010, Pages 949-956

  Yen, Yuan Peng ^a   Tsai, Keh Sung ^a   Chen, Ya Wen ^b   Huang, Chun Fa ^b   Yang, Rong Sen ^c   Liu, Shing Hwa ^a,c  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Akt signaling; Arsenic trioxide; Myogenic differentiation

Indexed keywords

ARSENIC TRIOXIDE; CREATINE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MYOGENIN; MYOSIN HEAVY CHAIN; PROTEIN KINASE B; S6 KINASE; GROWTH INHIBITOR; ORGANOARSENIC DERIVATIVE; OXIDE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; CULTURE MEDIUM; DOSE RESPONSE; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INCIDENCE; LOW BIRTH WEIGHT; MOUSE; MUSCLE DEVELOPMENT; MUSCLE REGENERATION; MYOPATHY; MYOTUBE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; SOLEUS MUSCLE; STAINING; ANIMAL; CELL DIFFERENTIATION; CELL SURVIVAL; CYTOLOGY; DRUG EFFECTS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; METABOLISM; MYOBLAST; PHOSPHORYLATION; PHYSIOLOGY; REGENERATION; TOXICITY;

MUS;

ANIMALS; ARSENICALS; CELL DIFFERENTIATION; CELL SURVIVAL; CELLS, CULTURED; CREATINE KINASE; DOSE-RESPONSE RELATIONSHIP, DRUG; GROWTH INHIBITORS; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MICE; MUSCLE, SKELETAL; MYOBLASTS; OXIDES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; REGENERATION; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION;

EID: 77954841660     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.0901525     Document Type: Article

References (52)

1. Bodine SC, Stitt TN, Gonzalez M, Kline WO, Stover GL, Bauerlein R, et al. 2001. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol 3:1014-1019.
2. Brameld JM, Mostyn A, Dandrea J, Stephenson TJ, Dawson JM, Buttery PJ, et al. 2000. Maternal nutrition alters the expression of insulin-like growth factors in fetal sheep liver and skeletal muscle. J Endocrinol 167:429-437.
3. Chakraborti D, Mukherjee SC, Pati S, Sengupta MK, Rahman MM, Chowdhury UK, et al. 2003. Arsenic groundwater contamination in Middle Ganga Plain, Bihar, India: a future danger? Environ Health Perspect 111:1194-1201.
4. Chan YS, Li Y, Foster W, Horaguchi T, Somogyi G, Fu FH, et al. 2003. Antifibrotic effects of suramin in injured skeletal muscle after laceration. J Appl Physiol 95:771-780.
5. Charbonnier F, Gaspera BD, Armand AS, Van der Laarse WJ, Launay T, Becker C, et al. 2002. Two myogenin-related genes are differentially expressed in Xenopus laevis myogenesis and differ in their ability to transactivate muscle structural genes. J Biol Chem 277:1139-1147.
6. Chen CJ, Wang SL, Chiou JM, Tseng CH, Chiou HY, Hsueh YM, et al. 2007. Arsenic and diabetes and hypertension in human populations: a review. Toxicol Appl Pharmacol 222:298-304.
7. 3 exerts dose-dependent dual effects on APL cells. Blood 89:3345-3353.
8. Davie JK, Cho JH, Meadows E, Flynn JM, Knapp JR, Klein WH. 2007. Target gene selectivity of the myogenic basic helix-loop-helix transcription factor myogenin in embryonic muscle. Dev Biol 311:650-664.
9. Diaz-Villasenor A, Burns AL, Hiriart M, Cebrian ME, Ostrosky-Wegman P. 2007. Arsenic-induced alteration in the expression of genes related to type 2 diabetes mellitus. Toxicol Appl Pharmacol 225:123-133.
10. Dummler B, Hemmings BA. 2007. Physiological roles of PKB/Akt isoforms in development and disease. Biochem Soc Trans 35(Pt 2):231-235.
11. Fahey AJ, Brameld JM, Parr T, Buttery PJ. 2005. The effect of maternal undernutrition before muscle differentiation on the muscle fiber development of the newborn lamb. J Anim Sci 83:2564-2571.
12. Franklin DS, Xiong Y. 1996. Induction of p18INK4c and its predominant association with CDK4 and CDK6 during myogenic differentiation. Mol Biol Cell 7:1587-1599.
13. Gonzalez I, Tripathi G, Carter EJ, Cobb LJ, Salih DA, Lovett FA, et al. 2004. Akt2, a novel functional link between p38 mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways in myogenesis. Mol Cell Biol 24:3607-3622.
14. Halevy O, Novitch BG, Spicer DB, Skapek SX, Rhee J, Hannon GJ, et al. 1995. Correlation of terminal cell cycle arrest ofskeletal muscle with induction of p21 by MyoD. Science 267:1018-1021.
15. Hurme T, Kalimo H. 1992. Activation of myogenic precursor cells after muscle injury. Med Sci Sports Exerc 24:197-205.
16. Institute of Laboratory Animal Resources. 1996. Guide for the Care and Use of Laboratory Animals. Washington, DC:National Academy Press.
17. Jensen CB, Martin-Gronert MS, Storgaard H, Madsbad S, Vaag A, Ozanne SE. 2008. Altered PI3-kinase/Akt signalling in skeletal muscle of young men with low birth weight. PLoS One 3:e3738; doi:10.1371/journal.pone.0003738 [Online 17 November 2008].
18. Jensen CB, Storgaard H, Madsbad S, Richter EA, Vaag AA. 2007. Altered skeletal muscle fiber composition and size precede whole-body insulin resistance in young men with low birth weight. J Clin Endocrinol Metab 92:1530-1534.
19. Jiang BH, Aoki M, Zheng JZ, Li J, Vogt PK. 1999. Myogenic signaling of phosphatidylinositol 3-kinase requires the serine-threonine kinase Akt/protein kinase B. Proc Natl Acad Sci USA 96:2077-2081.
20. Kachinskas DJ, Phillips MA, Qin Q, Stokes JD, Rice RH. 1994. Arsenate perturbation of human keratinocyte differentiation. Cell Growth Differ 5:1235-1241.
21. Kachinskas DJ, Qin Q, Phillips MA, Rice RH. 1997. Arsenate suppression of human keratinocyte programming. Mutat Res 386:253-261.
22. Kaliman P, Canicio J, Shepherd PR, Beeton CA, Testar X, Palacin M, et al. 1998. Insulin-like growth factors require phosphatidylinositol 3-kinase to signal myogenesis: dominant negative p85 expression blocks differentiation of L6E9 muscle cells. Mol Endocrinol 12:66-77.
23. Kaliman P, Vinals F, Testar X, Palacin M, Zorzano A. 1996. Phosphatidylinositol 3-kinase inhibitors block differentiation of skeletal muscle cells. J Biol Chem 271:19146-19151.
24. Kasemkijwattana C, Menetrey J, Somogyl G, Moreland MS, Fu FH, Buranapanitkit B, et al. 1998. Development of approaches to improve the healing following muscle contusion. Cell Transplant 7:585-598.
25. Kawai H, Nishino H, Kusaka K, Naruo T, Tamaki Y, Iwasa M. 1990. Experimental glycerol myopathy: a histological study. Acta Neuropathol 80(2):192-197.
26. Kuo ML, Chuang SE, Lin MT, Yang SY. 2001. The involvement of PI 3-K/Akt-dependent up-regulation of Mcl-1 in the prevention of apoptosis of Hep3B cells by interleukin-6. Oncogene 20:677-685.
27. Lai MS, Hsueh YM, Chen CJ, Shyu MP, Chen SY, Kuo TL, et al. 1994. Ingested inorganic arsenic and prevalence of diabetes mellitus. Am J Epidemiol 139:484-492.
28. Lassar AB, Skapek SX, Novitch B. 1994. Regulatory mechanisms that coordinate skeletal muscle differentiation and cell cycle withdrawal. Curr Opin Cell Biol 6:788-794.
29. McTernan CL, Draper N, Nicholson H, Chalder SM, Driver P, Hewison M, et al. 2001. Reduced placental 11 beta-hydroxysteroid dehydrogenase type 2 mRNA levels in human pregnancies complicated by intrauterine growth restriction: an analysis of possible mechanisms. J Clin Endocrinol Metab 86:4979-4983.
30. Myer A, Olson EN, Klein WH. 2001. MyoD cannot compensate for the absence of myogenin during skeletal muscle differentiation in murine embryonic stem cells. Dev Biol 229:340-350.
31. Navas-Acien A, Silbergeld EK, Streeter RA, Clark JM, Burke TA, Guallar E. 2006. Arsenic exposure and type 2 diabetes: a systematic review of the experimental and epidemiological evidence. Environ Health Perspect 114:641-648.
32. Olson EN, Perry M, Schulz RA. 1995. Regulation of muscle differentiation by the MEF2 family of MADS box transcription factors. Dev Biol 172:2-14.
33. Paul DS, Harmon AW, Devesa V, Thomas DJ, Styblo M. 2007. Molecular mechanisms of the diabetogenic effects of arsenic: inhibition of insulin signaling by arsenite and methylarsonous acid. Environ Health Perspect 115:734-742.
34. Peng XD, Xu PZ, Chen ML, Hahn-Windgassen A, Skeen J, Jacobs J, et al. 2003. Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev 17:1352-1365.
35. Qu-Petersen Z, Deasy B, Jankowski R, Ikezawa M, Cummins J, Pruchnic R, et al. 2002. Identification of a novel population of muscle stem cells in mice: potential for muscle regeneration. J Cell Biol 157:851-864.
36. Raghu KG, Cherian OL. 2009. Characterization of cytotoxicity induced by arsenic trioxide (a potent anti-APL drug) in rat cardiac myocytes. J Trace Elem Med Biol 23:61-68.
37. Rahman M, Tondel M, Ahmad SA, Axelson O. 1998. Diabetes mellitus associated with arsenic exposure in Bangladesh. Am J Epidemiol 148:198-203.
38. Rehfeldt C, Kuhn G. 2006. Consequences of birth weight for postnatal growth performance and carcass quality in pigs as related to myogenesis. J Anim Sci 84(suppl):E113-E123.
39. Rivard N. 2009. Phosphatidylinositol 3-kinase: a key regulatorin adherens junction formation and function. Front Biosci 14:510-522.
40. Ronco AM, Urrutia M, Montenegro M, Llanos MN. 2009. Cadmium exposure during pregnancy reduces birth weight and increases maternal and foetal glucocorticoids. Toxicol Lett 188:186-191.
41. Salazard B, Bellon L, Jean S, Maraninchi M, El-Yazidi C, Orsière T, et al. 2004. Low-level arsenite activates the transcription of genes involved in adipose differentiation. Cell Biol Toxicol 20:375-385.
42. Sandoval M, Morales M, Tapia R, del Carmen Alarcón L, Sordo M, Ostrosky-Wegman P, et al. 2007. p53 response to arsenic exposure in epithelial cells: protein kinase B/Akt involvement. Toxicol Sci 99: 126-140.
43. Seckl JR, Holmes MC. 2007. Mechanisms of disease: glucocorticoids, their placental metabolism and fetal programming of adult pathophysiology. Nat Clin Pract Endocrinol Metab 3:479-488.
44. Steiss JE, Wright JC, Cox NR. 1989. Effects of perinatal high dose dexamethasone on skeletal muscle development in rats. Can J Vet Res 53:1722.
45. Sumitani S, Goya K, Testa JR, Kouhara H, Kasayama S. 2002. Akt1 and Akt2 differently regulate muscle creatine kinase and myogenin gene transcription in insulin-induced differentiation of C2C12 myoblasts. Endocrinology 143:820-828.
46. Tamir Y, Bengal E. 2000. Phosphoinositide 3-kinase induces the transcriptional activity of MEF2 proteins during muscle differentiation. J Biol Chem 275:34424-34432.
47. Toker A, Newton AC. 2000. Cellular signaling: pivoting around PDK-1. Cell 103:185-188.
48. Trouba KJ, Wauson EM, Vorce RL. 2000. Sodium arsenite inhibits terminal differentiation of murine C3H 10T1/2 preadipocytes. Toxicol Appl Pharmacol 168:25-35.
49. Wang ZX, Jiang CS, Liu L, Wang XH, Jin HJ, Wu Q, et al. 2005. The role of Akt on arsenic trioxide suppression of 3T3-L1 preadipocyte differentiation. Cell Res 15:379-386.
50. Weintraub H. 1993. The MyoD family and myogenesis: redundancy, networks, and thresholds. Cell 75:1241-1244.
51. Weintraub H, Davis R, Tapscott S, Thayer M, Krause M, Benezra R, et al. 1991. The myoD gene family: nodal point during specification of the muscle cell lineage. Science 251:761-766.
52. Willhite CC, Ferm VH. 1984. Prenatal and developmental toxicology of arsenicals. Adv Exp Med Biol 177:205-228.